EGFR and non-small cell lung carcinoma: This validation indicates that specific genetic alterations in NSCLC patients can be reliably identified using Foundation One Liquid CDx, enabling personalized therapy with EGFR tyrosine kinase inhibitors such as erlotinib, gefitinib, and osimertinib (Woodhouse et al., 2020).